用于慢性自发性荨麻疹的在研药物。

Drugs in Development for Chronic Spontaneous Urticaria.

出版信息

J Drugs Dermatol. 2023 Apr 1;22(4):393-397. doi: 10.36849/JDD.7113.

Abstract

Chronic spontaneous urticaria (CSU) is a debilitating disease for which many patients are inadequately treated. However, recent advancements in our understanding of the disease pathophysiology allow us to develop therapies that are more effective for CSU. It may be possible in the future to select personalized treatments based on a patient’s autoimmune endotype. This paper reviews current knowledge on CSU pathogenesis and treatment. It also reviews data for drugs being developed for the treatment of CSU, as listed on ClinicalTrials.gov. J Drugs Dermatol. 2023;22(4): doi:10.36849/JDD.7113 Citation: Nguyen W, Liu W, Paul S. Yamauchi PS. Drugs in development for chronic spontaneous urticaria. J Drugs Dermatol. 2023;22(4):393-397. doi:10.36849/JDD.7113.

摘要

慢性自发性荨麻疹（CSU）是一种使人虚弱的疾病，许多患者的治疗效果并不理想。然而，我们对疾病病理生理学的理解的最新进展使我们能够开发出对 CSU 更有效的治疗方法。未来，我们有可能根据患者的自身免疫终末类型选择个性化的治疗方法。本文回顾了 CSU 发病机制和治疗的现有知识，并回顾了 ClinicalTrials.gov 上列出的用于治疗 CSU 的药物开发数据。J 皮肤病药物杂志。2023;22(4):doi:10.36849/JDD.7113 引文：Nguyen W, Liu W, Paul S. Yamauchi PS. 慢性自发性荨麻疹的开发药物。J 皮肤病药物杂志。2023;22(4):393-397.doi:10.36849/JDD.7113。